ARTICLE | Company News
J&J sales and marketing update
March 28, 2016 7:00 AM UTC
The U.K.’s NICE issued final guidance recommending Zytiga abiraterone from Johnson & Johnson to treat metastatic castration-resistant prostate cancer (CRPC) in patients whose first treatment has failed and for whom chemotherapy is not yet clinically indicated. The agency recommended against the inhibitor of steroidal enzyme 17 alpha-hydroxylase/C17, 20 lyase ( CYP17) in draft guidance, saying the incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY) gained compared to best supportive care was above the range considered an acceptable use of NHS resources (see BioCentury, Dec. 14, 2015). ...